市場調査レポート
商品コード
1226532
ポテリジオ薬品の考察と市場予測(2032年)POTELIGEO Drug Insight and Market Forecast - 2032 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
ポテリジオ薬品の考察と市場予測(2032年) |
出版日: 受注後更新
発行: DelveInsight
ページ情報: 英文 30 Pages
納期: 2~10営業日
|
当レポートでは、ポテリジオ薬品の主要7市場(米国・ドイツ・フランス・イタリア・スペイン・英国・日本)について調査分析し、作用機序、用法と用量、研究開発活動についての考察、市場予測などを提供しています。
"POTELIGEO Drug Insight and Market Forecast - 2032" report provides comprehensive insights about POTELIGEO for Cutaneous T-cell lymphoma (CTCL) in the seven major markets. A detailed picture of the POTELIGEO for Cutaneous T-cell lymphoma in the 7MM, i.e., the United States, EU4 (Germany, France, Italy and Spain) and the United Kingdom, and Japan for the study period 2019-2032 is provided in this report along with a detailed description of the POTELIGEO for Cutaneous T-cell lymphoma. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the POTELIGEO market forecast, analysis for Cutaneous T-cell lymphoma in the 7MM descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Cutaneous T-cell lymphoma.
POTELIGEO is used to treat adult patients with relapsed or refractory MF or SS after at least one prior systemic therapy. It is marketed in Japan for the treatment of relapsed or refractory CTCL.
Mogamulizumab is a recombinant humanized monoclonal antibody composed of complementarity-determining regions derived from mouse anti-human CC chemokine receptor 4 monoclonal antibody and framework regions and constant regions derived from human IgG1. It is produced in Chinese hamster ovary cells. It is a glycoprotein (molecular weight: ca. 149,000) composed of 2 H chain (γ1- chain) molecules consisting of 449 amino acid residues each and 2 L-chain (κ-chain) molecules consisting of 219 amino acid residues each.
It is a humanized anti-CCR4 defucosylated IgG1 mAb that eliminates tumor cells via ADCC. Using the mechanism, nonspecific effector cells, including natural killer (NK) cells and macrophages/monocytes, possess membrane-bound FcγRs that crosslink with the Fc region of the IgG molecule, bound to a specific target cancer cell, such as the CCR4+ lymphoma cell. FcγR binding increases the activity of the cytotoxic cells, facilitating the release of cytoplasmic lytic enzymes, granzymes, perforin-containing granules, and tumor necrosis factor (TNF) that induce lysis of the antibody-targeted cell.
Dosage and Administration
The recommended dosage of POTELIGEO is 1 mg/kg and is administered as an intravenous infusion over at least 60 minutes. The drug is administered on Days 1, 8, 15, and 22 of the first 28-day cycle, then on Days 1 and 15 of each subsequent 28-day cycle until disease progression or unacceptable toxicity. The drug (POTELIGEO) is administered within 2 days of the scheduled dose. If a dose is missed, administer the next dose as soon as possible and resume the dosing schedule. It is advised not to administer POTELIGEO subcutaneously or by rapid intravenous administration.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
POTELIGEO Analytical Perspective by DelveInsight
This report provides a detailed market assessment of POTELIGEO in Cutaneous T-cell lymphoma in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.
The report provides the clinical trials information of POTELIGEO in Cutaneous T-cell lymphoma covering trial interventions, trial conditions, trial status, start and completion dates.
Key Questions